Savara to present new data from pivotal phase 3 impala-2 trial of molgramostim nebulizer solution (molgramostim) in patients with autoimmune pulmonary alveolar proteinosis (apap) at the european respiratory society (ers) congress 2024

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of an abstract for poster presentation at the european respiratory society (ers) congress 2024, taking place september 7-11, 2024, in vienna, austria. the company is also sponsoring an industry symposium at the congress. details are as follows: accepted abstract title: “inhaled molgramostim improves pulmonary g.
SVRA Ratings Summary
SVRA Quant Ranking